Results 301 to 310 of about 935,466 (405)

Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Phenoconversion, a genotype‐phenotype mismatch, challenges a successful implementation of personalized medicine. The aim of this study was to detect and determine phenoconversion using the solanidine metabolites 3,4‐seco‐solanidine‐3,4‐dioic acid (SSDA) and 4‐OH‐solanidine as diet‐derived cytochrome P450 2D6 (CYP2D6) biomarkers in a ...
Jens Andreas Sarömba   +9 more
wiley   +1 more source

Effect of hydration schedules on dose‐limiting toxicity in patients with head and neck squamous cell carcinoma treated with cisplatin

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of this study was to determine if head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin chemoradiotherapy and short hydration (SH) experience less dose‐limiting toxicity (DLT) and receive more cisplatin than those with medium hydration (MH) or long hydration (LH).
Anouk W. M. A. Schaeffers   +10 more
wiley   +1 more source

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this phase 1 trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone (previously AZD9977) in participants with severe renal impairment vs. those with normal renal function. Methods Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2) not on dialysis were ...
Chandrali S. Bhattacharya   +10 more
wiley   +1 more source

Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B‐cell malignancies

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of this study was to assess differences between Chinese and White patients in pharmacokinetics (PK) of, and clinical response to, acalabrutinib and its pharmacologically active major metabolite, ACP‐5862, to support recommended dosing in Chinese patients with B‐cell malignancies.
Tingting Yao   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy